

MAIN POINT OF CONTACTName: _____
Phone: _____DERMATOLOGY
Ph: 832-365-3420 Fax: 855-595-2955Injection Training: ☐ MD Office
☐ Pharmacy to ArrangeShip To : ☐ Patient Home ☐ MD Office**PATIENT INFORMATION (Use this area or attach patient demographics)**Name: _____ Phone: _____ Phone 2: _____
Home Address: _____ City: _____ State: _____ Zip Code: _____
DOB: _____ SSN: _____ Sex: ☐ Male ☐ Female Height: _____
Weight: _____ lbs. Emergency Contact: _____
Phone: _____**INSURANCE INFORMATION (Use this area or attach copy of insurance card(s))**

Primary Insurance:		Secondary Insurance:	
ID#:	RxBin:	ID#:	RxBin:
RxGroup:	Pcn:	RxGroup:	Pcn:

MEDICAL ASSESSMENT (Use this area or attach patient labs and other authorization information)

Primary Diagnosis: _____ ICD10 Code: _____

PRESCRIPTION INFORMATION *(Use this area or attach copy of RX(s))

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
☐ AKLIEF	☐ .005% CREAM	☐ APPLY A THIN LAYER OF CREAM TO AFFECTED AREAS ONCE DAILY IN THE EVENING, ON CLEAN AND DRY SKIN	[45] gram pump	
☐ ALTRENO	☐ .05% LOTION	☐ APPLY A THIN LAYER OF LOTION TO AFFECTED AREAS ONCE DAILY	[20] or [45] gram bottle	
☐ AMZEEQ	☐ 4% FOAM	☐ APPLY TO AFFECTED AREAS ONCE DAILY	[30] gram can	
☐ ARAZLO	☐ .045% LOTION		[45] gram bottle	
☐ BIMZELX	☐ 160MG PFS ☐ 160MG AUTOINJECTOR ☐ 320MG PFS ☐ 320MG AUTOINJECTOR	☐ INJECT _____ MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	
☐ BRYHALI	☐ .01% LOTION	☐ APPLY A THIN LAYER OF LOTION TO AFFECTED AREAS ONCE DAILY	[60] or [100] gram tube	
☐ CABTREO	☐ 1.2%/1.5%/3.15% GEL	☐ APPLY A THIN LAYER OF GEL TO AFFECTED AREAS ONCE DAILY	[50] gram pump	
☐ CIBINQO	☐ 50MG TABLET ☐ 100MG TABLET ☐ 200MG TABLET	☐ TAKE 1 TABLET BY MOUTH ONCE DAILY	[30]	
☐ CIMZIA	☐ 200MG PFS ☐ 200MG SDV	☐ INJECT _____ MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	

ALL controlled substance quantities must be hand written in number and letter formPrescriber Name: _____ NPI#: _____
Address: _____ City: _____ State: _____ Zip Code: _____
Phone: _____ Fax: _____***Prescriber Signature:****Date:**

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone numbers set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.

Please fax completed form to 1 (855) 595-2955

MAIN POINT OF CONTACT

Name: _____
 Phone: _____



DERMATOLOGY
 Ph: 832-365-3420 Fax: 855-595-2955

Injection Training: ☐ MD Office
☐ Pharmacy to Arrange

Ship To : ☐ Patient Home ☐ MD Office

PATIENT INFORMATION (Use this area or attach patient demographics)

Name: _____ Phone: _____ Phone 2: _____
 Home Address: _____ City: _____ State: _____ Zip Code: _____
 DOB: _____ SSN: _____ Sex: ☐ Male ☐ Female Height: _____
 Weight: _____ lbs. Emergency Contact: _____
 Phone: _____

INSURANCE INFORMATION (Use this area or attach copy of insurance card(s))

Primary Insurance:		Secondary Insurance:	
ID#:	RxBin:	ID#:	RxBin:
RxGroup:	Pcn:	RxGroup:	Pcn:

MEDICAL ASSESSMENT (Use this area or attach patient labs and other authorization information)

Primary Diagnosis: _____ ICD10 Code: _____

PRESCRIPTION INFORMATION *(Use this area or attach copy of RX(s))

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
☐ COSENTYX	☐ 150MG PFS ☐ 150MG PEN ☐ 300MG PFS ☐ 300MG PEN	☐ INJECT _____ MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	
☐ DENAVIR	☐ 1% CREAM	☐ APPLY CREAM EVERY 2 HOURS DURING WAKING HOURS FOR A PERIOD OF 4 DAYS	[5] gram tube	
☐ DUOBRII	☐ .01%/.045% LOTION	☐ APPLY A THIN LAYER OF LOTION TO AFFECTED AREAS ONCE DAILY	[100] gram tube	
☐ DUPIXENT	☐ 200MG PFS ☐ 200MG AUTOINJECTOR ☐ 300MG PFS ☐ 300MG AUTOINJECTOR	☐ INJECT _____ MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	
☐ DRY SOL	☐ 20% DAB-O-MATIC DEVICE ☐ 20% SOLUTION	☐ APPLY A THIN LAYER ONCE DAILY USING THE PROVIDED APPLICATOR OR A COTTON BALL	35ml device 60ml device	
☐ EBGlySS	☐ 250MG PFS ☐ 250MG PEN	☐ INJECT _____ MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	

ALL controlled substance quantities must be hand written in number and letter form

Prescriber Name: _____ NPI#: _____
 Address: _____ City: _____ State: _____ Zip Code: _____
 Phone: _____ Fax: _____

Prescriber Signature:*Date:**

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone numbers set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.

Please fax completed form to 1 (855) 595-2955

MAIN POINT OF CONTACTName: _____
Phone: _____**DERMATOLOGY**

Ph: 832-365-3420 Fax: 855-595-2955

Injection Training: ☐ MD Office☐ Pharmacy to ArrangeShip To : ☐ Patient Home ☐ MD Office**PATIENT INFORMATION (Use this area or attach patient demographics)**Name: _____ Phone: _____ Phone 2: _____
Home Address: _____ City: _____ State: _____ Zip Code: _____
DOB: _____ SSN: _____ Sex: ☐ Male ☐ Female Height: _____
Weight: _____ lbs. Emergency Contact: _____
Phone: _____**INSURANCE INFORMATION (Use this area or attach copy of insurance card(s))**

Primary Insurance:		Secondary Insurance:	
ID#:	RxBin:	ID#:	RxBin:
RxGroup:	Pcn:	RxGroup:	Pcn:

MEDICAL ASSESSMENT (Use this area or attach patient labs and other authorization information)

Primary Diagnosis: _____ ICD10 Code: _____

PRESCRIPTION INFORMATION *(Use this area or attach copy of RX(s))

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
☐ ENBREL	☐ 25MG SDV ☐ 25MG PFS ☐ 50MG AUTOINJECTOR ☐ 50MG PFS ☐ 50MG MINI CARTRIDGE	☐ INJECT _____MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	
☐ ENSTILAR	☐ .005%/.064% FOAM	☐ APPLY FOAM TO AFFECTED AREA(S) ONCE DAILY FOR UP TO 4 WEEKS	[60] or [120] gram can	
☐ EUCRISA	☐ 2% OINTMENT	☐ APPLY A THIN LAYER TWICE DAILY TO AFFECTED AREAS	[60] or [100] gram tube	
☐ HUMIRA CF	☐ 40MG PFS ☐ 40MG PEN ☐ 80MG PFS ☐ 80MG PEN	☐ INJECT _____MG SQ EVERY _____ WEEKS, FOR _____ WEEKS	[QS 4 WEEK SUPPLY]	
☐ ILUMYA	☐ 100MG PFS	☐ INJECT 100 MG SQ AT WEEKS 0, 4, AND EVERY 12 WEEKS THEREAFTER	[QS 4 WEEK SUPPLY]	
☐ ISOTRETINOIN (please specify brand preference) _____	☐ 10MG CAPSULE ☐ 20MG CAPSULE ☐ 30MG CAPSULE ☐ 40MG CAPSULE			

ALL controlled substance quantities must be hand written in number and letter form

Prescriber Name: _____ NPI#: _____

Address: _____ City: _____ State: _____ Zip Code: _____

Phone: _____ Fax: _____

Prescriber Signature:*Date:**

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone numbers set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.

Please fax completed form to 1 (855) 595-2955

MAIN POINT OF CONTACTName: _____
Phone: _____**DERMATOLOGY**
Ph: 832-365-3420 Fax: 855-595-2955Injection Training: ☐ MD Office
☐ Pharmacy to ArrangeShip To : ☐ Patient Home ☐ MD Office**PATIENT INFORMATION (Use this area or attach patient demographics)**Name: _____ Phone: _____ Phone 2: _____
Home Address: _____ City: _____ State: _____ Zip Code: _____
DOB: _____ SSN: _____ Sex: ☐ Male ☐ Female Height: _____
Weight: _____ lbs. Emergency Contact: _____
Phone: _____**INSURANCE INFORMATION (Use this area or attach copy of insurance card(s))**

Primary Insurance:		Secondary Insurance:	
ID#:	RxBin:	ID#:	RxBin:
RxGroup:	Pcn:	RxGroup:	Pcn:

MEDICAL ASSESSMENT (Use this area or attach patient labs and other authorization information)

Primary Diagnosis: _____ ICD10 Code: _____

PRESCRIPTION INFORMATION *(Use this area or attach copy of RX(s))

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
☐ JUBLIA	☐ 10% SOLUTION	☐ APPLY TO AFFECTED TOENAILS ONCE DAILY USING THE INTEGRATED FLOW-THROUGH BRUSH APPLICATOR	[4] or [8] ML SOLUTION	
☐ KLISYRI	☐ 1% OINTMENT	☐ APPLY OINTMENT TO THE TREATMENT FIELD ON THE FACE OR SCALP ONCE DAILY FOR 5 CONSECUTIVE DAYS USING 1 UNIT-DOSE PACKET PER APPLICATION	[5] UNIT DOSE PACKETS	
☐ ODOMZO	☐ 200MG CAPSULE	☐ TAKE 1 TABLET BY MOUTH ONCE DAILY	[30]	
☐ ONEXTON	☐ 1.2%/3.75% GEL	☐ APPLY A PEA-SIZED AMOUNT GEL TO THE FACE ONCE DAILY	[50] gram pump	
☐ OPZELURA	☐ 1.5% CREAM	☐ APPLY A THIN LAYER OF CREAM TOPICALLY TWICE DAILY TO AFFECTED AREAS OF UP TO 20% BODY SURFACE AREA ☐ APPLY A THIN LAYER OF CREAM TOPICALLY TWICE DAILY TO AFFECTED AREAS OF UP TO 10% BODY SURFACE AREA	[60] gram tube	
☐ OTEZLA	☐ STARTER PACK ☐ 20MG TABLET ☐ 30MG TABLET	☐ FOLLOW PACKAGE INSTRUCTIONS AND USE AS DIRECTED BY PHYSICIAN ☐ TAKE _____MG BY MOUTH _____TIME(S) PER DAY		
☐ OTEZLA XR	☐ STARTER PACK ☐ 75MG TABLET	☐ FOLLOW PACKAGE INSTRUCTIONS AND USE AS DIRECTED BY PHYSICIAN ☐ TAKE _____MG BY MOUTH _____TIME(S) PER DAY		
☐ RHAPSIDO	☐ 25MG TABLET	☐ TAKE 1 TABLET BY MOUTH TWICE DAILY	60 Tablets	
☐ RHOFADE	☐ 1% CREAM	☐ APPLY A PEA-SIZED AMOUNT OF CREAM, ONCE DAILY IN A THIN LAYER TO COVER THE ENTIRE FACE	[30] gram tube	
☐ RINVOQ	☐ 15MG ER TABLET ☐ 30MG ER TABLET	☐ TAKE _____MG BY MOUTH ONCE DAILY	[30]	

ALL controlled substance quantities must be hand written in number and letter formPrescriber Name: _____ NPI#: _____
Address: _____ City: _____ State: _____ Zip Code: _____
Phone: _____ Fax: _____***Prescriber Signature:** _____**Date:** _____

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone numbers set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.

Please fax completed form to 1 (855) 595-2955

MAIN POINT OF CONTACTName: _____
Phone: _____**DERMATOLOGY**
Ph: 832-365-3420 Fax: 855-595-2955Injection Training: ☐ MD Office
☐ Pharmacy to ArrangeShip To : ☐ Patient Home ☐ MD Office**PATIENT INFORMATION (Use this area or attach patient demographics)**Name: _____ Phone: _____ Phone 2: _____
Home Address: _____ City: _____ State: _____ Zip Code: _____
DOB: _____ SSN: _____ Sex: ☐ Male ☐ Female Height: _____
Weight: _____ lbs. Emergency Contact: _____
Phone: _____**INSURANCE INFORMATION (Use this area or attach copy of insurance card(s))**

Primary Insurance:		Secondary Insurance:	
ID#:	RxBin:	ID#:	RxBin:
RxGroup:	Pcn:	RxGroup:	Pcn:

MEDICAL ASSESSMENT (Use this area or attach patient labs and other authorization information)

Primary Diagnosis: _____ ICD10 Code: _____

PRESCRIPTION INFORMATION *(Use this area or attach copy of RX(s))

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
☐ SILIQ	☐ 210MG PFS	☐ LOAD: INJECT 210MG SUBCUTANEOUSLY ON WEEKS 0, 1, AND 2, THEN EVERY 2 WEEKS THEREAFTER ☐ MAINTENANCE: INJECT 210MG SUBCUTANEOUSLY EVERY 2 WEEKS	[QS 4 WEEK SUPPLY]	
☐ SIVEXTRO	☐ 200MG TABLET ☐ 200MG SDV		[6]	
☐ SEYSARA	☐ 60MG TABLET ☐ 100MG TABLET ☐ 150MG TABLET	☐ TAKE 1 TABLET BY MOUTH ONCE DAILY		
☐ SIMPOINI	☐ 50MG PFS ☐ 50MG SMARTJECT	☐ INJECT 50MG SUBCUTANEOUSLY ONCE A MONTH AS DIRECTED	[QS 4 WEEK SUPPLY]	
☐ SKYRIZI	☐ 150MG PFS ☐ 150MG PEN	☐ STARTER: INJECT 150MG SUBCUTANEOUSLY ON WEEK 0 ☐ MAINTENANCE: INJECT 150MG SUBCUTANEOUSLY ON WEEK 4, THEN EVERY 12 WEEKS THEREAFTER	[QS 4 WEEK SUPPLY]	
☐ SOTYKTU	☐ 6MG TABLET	☐ TAKE 1 TABLET BY MOUTH ONCE DAILY		
☐ STELARA	☐ 45MG VIAL ☐ 45MG PFS ☐ 90MG PFS	☐ STARTER: INJECT ____MG SUBCUTANEOUSLY ON WEEK 0 ☐ MAINTENANCE: INJECT ____MG ON WEEK 4, THEN EVERY 12 WEEKS THEREAFTER	[QS 4 WEEK SUPPLY]	
☐ TALTZ	☐ 80MG PFS ☐ 80MG AUTOINJECTOR	☐ INJECT ____MG SQ EVERY ____ WEEKS	[QS 4 WEEK SUPPLY]	

ALL controlled substance quantities must be hand written in number and letter formPrescriber Name: _____ NPI#: _____
Address: _____ City: _____ State: _____ Zip Code: _____
Phone: _____ Fax: _____***Prescriber Signature:****Date:**

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone numbers set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.

Please fax completed form to 1 (855) 595-2955

MAIN POINT OF CONTACTName: _____
Phone: _____**DERMATOLOGY**
Ph: 832-365-3420 Fax: 855-595-2955Injection Training: ☐ MD Office
☐ Pharmacy to ArrangeShip To : ☐ Patient Home ☐ MD Office**PATIENT INFORMATION (Use this area or attach patient demographics)**Name: _____ Phone: _____ Phone 2: _____
Home Address: _____ City: _____ State: _____ Zip Code: _____
DOB: _____ SSN: _____ Sex: ☐ Male ☐ Female Height: _____
Weight: _____ lbs. Emergency Contact: _____
Phone: _____**INSURANCE INFORMATION (Use this area or attach copy of insurance card(s))**

Primary Insurance:		Secondary Insurance:	
ID#:	RxBin:	ID#:	RxBin:
RxGroup:	Pcn:	RxGroup:	Pcn:

MEDICAL ASSESSMENT (Use this area or attach patient labs and other authorization information)

Primary Diagnosis: _____ ICD10 Code: _____

PRESCRIPTION INFORMATION *(Use this area or attach copy of RX(s))

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
☐ TWYNEO	☐ 0.1%/3% CREAM	☐ APPLY A THIN LAYER OF CREAM TO AFFECTED AREAS ONCE DAILY	[30] gram pump	
☐ TREMFYA	☐ 100MG PFS ☐ 100MG ONE TOUCH INJECTOR	☐ STARTER: INJECT 100MG SUBCUTANEOUSLY ON WEEK 0 ☐ MAINTENANCE: INJECT 100MG SUBCUTANEOUSLY ON WEEK 4, THEN EVERY 8 WEEKS THEREAFTER	[QS 4 WEEK SUPPLY]	
☐ VTAMA	☐ 1% CREAM	☐ APPLY A THIN LAYER OF CREAM TO AFFECTED AREAS ONCE DAILY	[60] gram tube	
☐ WINLEVI	☐ 1% CREAM	☐ APPLY A THIN LAYER (APPROXIMATELY 1 GRAM) TO AFFECTED AREA TWICE DAILY (MORNING AND EVENING)	[60] gram tube	
☐ WYNZORA	☐ .005%/.064% CREAM	☐ APPLY CREAM TO AFFECTED AREAS ONCE DAILY FOR UP TO 8 WEEKS	[60] gram tube	
☐ XELJANZ	☐ 5MG TABLET ☐ 11MG XR TABLET	☐ TAKE _____ TABLET(S) BY MOUTH _____ DAILY		
☐ YCANTH	☐ .7% SOLUTION	☐ TO BE ADMINISTERED BY HCP	1 KIT	
☐ ZILXI	☐ 1.5% FOAM	☐ APPLY FOAM OVER ALL AREAS OF THE FACE ONCE DAILY	[30] gram can	
☐ ZELSUVMI	☐ 10.3% GEL	☐ FOLLOW PACKAGE INSTRUCTIONS AND USE AS DIRECTED BY PHYSICIAN	1 KIT	
☐ ZORYVE	☐ .05% CREAM ☐ .15% CREAM ☐ .3% CREAM ☐ .3% FOAM	☐ APPLY TO AFFECTED AREAS ONCE DAILY	60 GRAMS	

ALL controlled substance quantities must be hand written in number and letter formPrescriber Name: _____ NPI#: _____
Address: _____ City: _____ State: _____ Zip Code: _____
Phone: _____ Fax: _____***Prescriber Signature:** _____**Date:** _____

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone numbers set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.

Please fax completed form to 1 (855) 595-2955